The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Open accessPublished version of a preprint
Abstract
Purpose: Our preclinical studies showed that the PARP inhibitor, olaparib, prior to carboplatin attenuated carboplatin cytotoxicity. We evaluated sequence-specific pharmacokinetic and pharmacodynamic effects, safety, and activity of the combination. Experimental Design: Eligible patients had metastatic or recurrent women's cancer. Olaparib tablets were introduced (100 or 200 mg twice daily, days 1–7) in a 3 + 3 dose escalation with carboplatin AUC4 or 5 every 21 days, up to eight cycles, followed by olaparib 300 mg twice daily maintenance. Patients were randomly assigned to starting schedule: cohort A (olaparib days 1–7, carboplatin on day 8) or B (carboplatin on day 1, olaparib days 2–8) during cycle 1. Patients received the reversed scheme in cycle 2. Blood was collected for olaparib pharmacokinetics, platinum–DNA adducts, comet assay, and PAR concentrations. The primary objectives were to examine schedule-dependent effects on olaparib pharmacokinetics and platinum–DNA adducts. Results: A total of 77 (60 ovarian, 14 breast, and 3 uterine cancer) patients were treated. Dose-limiting toxicity was thrombocytopenia and neutropenia, defining olaparib 200 mg twice daily + carboplatin AUC4 as the MTD. Olaparib clearance was increased approximately 50% when carboplatin was given 24 hours before olaparib. In vitro experiments demonstrated carboplatin preexposure increased olaparib clearance due to intracellular olaparib uptake. Quantities of platinum–DNA adducts were not different as a function of the order of drug administration. Responses included 2 CRs and 31 PRs (46%) with a higher RR in BRCA mutation carriers compared with nonmutation carriers (68% vs. 19%). Conclusions: Tablet olaparib with carboplatin is a safe and active combination. Carboplatin preexposure causes intracellular olaparib accumulation reducing bioavailable olaparib, suggesting carboplatin should be administered prior to olaparib. Clin Cancer Res; 23(6); 1397–406. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacokinetic data from the trial suggested that administering carboplatin before olaparib may be the preferred treatment schedule to enhance the overall clinical benefit of this combination therapy, as pre-exposure to carboplatin causes intracellular accumulation of olaparib (P = 0.013), thereby improving its effective availability within tumour cells.”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Cited by
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Kurnit, K. C., Fleming, G. F., & Lengyel, E. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004173 · Cited by 322
PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline
Tew, W. P., Lacchetti, C., Ellis, A., Maxian, K., Banerjee, S., Bookman, M., Jones, M. B., Lee, J.-M., Lheureux, S., Liu, J. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01924 · Cited by 315
Self-citationLee, J.-M., Cimino-Mathews, A., Peer, C. J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 242
Self-citationDrew, Y., Zenke, F. T., & Curtin, N. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01060-w · Cited by 229
Lee, J.-M., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30009-3 · Cited by 209
Self-citation
Metadata
- Authors
- Lee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., Minasian, L., Chiou, V. L., Murphy, R. F., Widemann, B. C., Figg, W. D., & Kohn, E. C.
- Affiliations
- National Cancer Institute (US)
- National Institute on Minority Health and Health Disparities (US)
- National Institutes of Health (US)
- Corresponding author
- Lee, Jung-Min
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-03-14
- Volume
- 23
- Issue
- 6
- Pages
- 1397-1406
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5354956
- OpenAlex
- W2521351716
- Cited by
- 56
- References
- 34
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 6 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 7
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC011525)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- olaparib, carboplatin, PARP inhibitors, drug sequence, pharmacokinetics, pharmacodynamics, platinum-DNA adducts, ovarian cancer, breast cancer, uterine cancer, BRCA mutation carriers, dose-limiting toxicity, thrombocytopenia, neutropenia, intracellular drug accumulation, maintenance therapy, women's cancer, combination chemotherapy, dose escalation
- MeSH terms
- Adult, Aged, Breast Neoplasms, Drug Administration Schedule, Female, Humans, Leukocytes, Mononuclear, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Phthalazines, Piperazines, Uterine Neoplasms, Carboplatin, DNA Adducts, Maximum Tolerated Dose, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1546
- The paper
- Lee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., Minasian, L., Chiou, V. L., Murphy, R. F., Widemann, B. C., Figg, W. D., & Kohn, E. C. (2017). Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.